Replies to post #14288 on Hard to Treat Diseases (HTDS)

[Ubertino]

The headline:

Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million

It is convoluted, alright!

But clear enough if you know about Mellow Hope - the subsid - and Tianyuan - their partner.

But it is clear they did not buy ANY of HTDS.